DLBCL

EHA 2019 | Real world data from the first French cohort of patients treated with CAR T-cell therapy

L:

At the 24th Congress of the European Hematology Association (EHA), Catherine Thieblemont from the Hôpital Saint-Louis, Paris, FR, reports on the first French patients treated with CAR T.

These patients were treated on a compassionate programme and all had relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Having enrolled 60 patients in 5 centers, 53 were treated due to early progression in 7 patients.

Professor Thieblemont notes the very promising results of these patients in relation to progression-free survival and an overall survival rate at 3 months of 80%.